NEW YORK, Dec. 1, 2010 /PRNewswire-FirstCall/ -- Delcath Systems, Inc. (Nasdaq: DCTH) today announced the appointment of Bernard R. Tyrrell to the newly created position of Senior Vice President – North American Sales and Marketing. In this role, Mr. Tyrrell will lead the development of Delcath's sales, marketing and clinical support teams, as well as the formulation of the reimbursement strategy for the Company's chemosaturation system in the United States. Mr. Tyrrell will report directly to Agustin Gago, Executive Vice President - Global Sales & Marketing.
"Bernie has a proven track record in devising successful business development strategies for specialty oncology medicines in both international and domestic markets, and we are pleased to welcome him to the Delcath team," said Eamonn P. Hobbs, CEO & President of Delcath Systems. "Bernie has led commercialization efforts for many important oncology brands, such as Gemzar® Arimidex®, Faslodex®, Casodex®, Zoladex®, Iressa® and Busulfex®. We believe Bernie's background as a registered pharmacist, combined with his deep commercial expertise in oncology, will be beneficial to us as we look to build our sales, clinical support, and reimbursement organizations next year."
Prior to joining Delcath, Mr. Tyrrell, 56, was Senior Vice President of Sales and Marketing at EpiCept Corporation, where he led the commercialization plans for the company's oncology and pain management platforms. Previously, he was Vice President of Oncology at Otsuka America Pharmaceutical, Inc., and Vice President of Global Marketing, Breast Cancer and Infection at AstraZeneca Pharmaceuticals. While at AstraZeneca, Mr. Tyrrell led the development and commercialization of global breast cancer products totaling $2.2 billion in sales. Mr. Tyrrell has also held marketing and sales leadership positions at Johnson & Johnson and Eli Lilly & Company.
Mr. Tyrrell earned a Bachelor of Science in Pharmacy from the Massachusetts College of Pharmacy, and an MBA in Marketing Management from Bryant College.About Delcath Systems Delcath Systems, Inc. is a development stage, specialty pharmaceutical and medical device company focused on oncology. Delcath's proprietary system for chemosaturation is designed to administer high dose chemotherapy and other therapeutic agents to diseased organs or regions of the body, while controlling the systemic exposure of those agents. The Company's initial focus is on the treatment of primary and metastatic liver cancers. In 2010, Delcath concluded a Phase III metastatic melanoma study, and the Company recently completed a multi–arm Phase II trial to treat other liver cancers. The Company has not yet received FDA or any foreign regulatory approval for commercial sale of its system. For more information, please visit the Company's website at www.delcath.com. The Private Securities Litigation Reform Act of 1995 provides a safe harbor for forward–looking statements made by the Company or on its behalf. This news release contains forward–looking statements, which are subject to certain risks and uncertainties that can cause actual results to differ materially from those described. Factors that may cause such differences include, but are not limited to, uncertainties relating to the acceptability of the Phase III clinical trial data by the FDA, our ability to successfully complete an FDA new drug application, acceptance of the new drug application by the FDA, approval by the FDA or other regulatory authorities of the current or future drug delivery system for the treatment of metastatic melanoma, our ability to successfully complete other clinical trials and secure regulatory approval of our current or future drug–delivery system for the treatment of other liver cancers and other organs, the potential of chemosaturation therapy via PHP as a treatment for patients with terminal metastatic disease in the liver, actions by the FDA or other regulatory agencies, our ability to successfully enter into distribution and strategic partnership agreements in foreign markets and the corresponding revenue associated with such foreign markets, and uncertainties regarding our ability to obtain financial and other resources for any research, development and commercialization activities. These factors, and others, are discussed from time to time in our filings with the Securities and Exchange Commission. You should not place undue reliance on these forward–looking statements, which speak only as of the date they are made. We undertake no obligation to publicly update or revise these forward–looking statements to reflect events or circumstances after the date they are made. SOURCE Delcath Systems, Inc.